Cambridge Cognition Holdings PLC Senior Management Appointments (3951H)
06 Abril 2022 - 1:01AM
UK Regulatory
TIDMCOG
RNS Number : 3951H
Cambridge Cognition Holdings PLC
06 April 2022
Cambridge Cognition Holdings plc
("Cambridge Cognition" or the "Company")
Senior Management Appointments
Cambridge Cognition Holdings plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce two senior management appointments.
Stephen Symonds has joined the Company as its new Chief
Financial Officer and is expected to join the board in due course.
Stephen is an experienced finance professional and was until
recently the Chief Financial Officer of Envigo, a private equity
backed provider of pre-clinical services for the pharmaceutical
industry, where he spent eight years. Prior to that, Stephen spent
a decade with KPMG, working on a wide-ranging portfolio of clients.
Earlier in his career, he built a broad experience in a variety of
small to medium-size accounting companies and as the finance lead
in a family-owned business.
The board would like to thank Nick Walters for providing the
Company with interim financial leadership while the Chief Financial
Officer recruitment process was conducted.
Francesca Cormack has been appointed as the Company's Chief
Scientist, having spent seven years at Cambridge Cognition, most
recently as Director of Research and Innovation. Francesca will
lead the Company's research and development activities and act as
the Company's scientific leader, with a view to enhancing its
competitive position and supporting its long-term business success.
She is also an honorary senior research fellow at Cambridge
University's department of psychiatry.
Jenny Barnett, currently Chief Scientific Officer, will be
stepping down from the Company at the end of April 2022 to focus
her efforts on Monument Therapeutics. Monument Therapeutics was
spun out from Cambridge Cognition in July 2021 and continues to
work closely with the Company using its cognitive assessments as
core elements of their developments.
For further information, contact:
Cambridge Cognition Holdings Plc Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Steven Powell, Chairman
Panmure Gordon (NOMAD and Joint Broker) Tel: 020 7886 2500
Freddy Crossley / Emma Earl / Mark Rogers (Corporate Advisory)
Rupert Dearden (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital
health products to better understand, detect and treat conditions
affecting brain health. The Company's software products assess
cognitive health in patients worldwide to improve clinical trial
outcomes, identify and stratify patients early and improve global
efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEANLSELDAEFA
(END) Dow Jones Newswires
April 06, 2022 02:01 ET (06:01 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De May 2023 a May 2024